< Volver

Resumen

Indolent metastatic medullary thyroid carcinoma: to treat or not to treat. Clinical case.

Carcinoma medular de tiroides indolente: tratar o no tratar

VOLUMEN 4 - NÚMERO 3 / Julio - Septiembre (Caso Clí­nico)


Latife Salame, Cancer Center, American British Cowdray Medical Center, Mexico City, Mexico
Dalia Cuenca, Cancer Center, American British Cowdray Medical Center, Mexico City, Mexico
Carolina Blanco, Cancer Center, American British Cowdray Medical Center, Mexico City, Mexico
Raquel Gerson, Cancer Center, American British Cowdray Medical Center, Mexico City, Mexico
Moisés Mercado, Neurological Center, American British Cowdray Medical Center and Endocrinology Service/Experimental Endocrinology Unit, Hospital de Especialidades, Centro Médico Nacional S.XXI, IMSS

Medullary thyroid carcinoma occurring either sporadically or in the context of Type 2A multiple endocrine neoplasia can follow a relatively indolent and asymptomatic course over many years, including some cases with metastatic disease. Although treatment with the recently approved tyrosine-kinase inhibitors is an option, the decision to indicate them should weight the potential benefits against the potential adverse events of these costly targeted therapies with consideration of the patient’s wishes.

Palabras clave: Medullary thyroid carcinoma. Type 2A multiple endocrine neoplasia. Pheochromocytoma. RET proto-oncogene. Tyrosine-kinase inhibitors.

Artículo completo en PDF